Stewart Alan Factor
#149,103
Most Influential Person Now
Stewart Alan Factor's AcademicInfluence.com Rankings
Stewart Alan Factorphilosophy Degrees
Philosophy
#8168
World Rank
#11496
Historical Rank
Logic
#5198
World Rank
#6577
Historical Rank

Download Badge
Philosophy
Stewart Alan Factor's Degrees
- Doctorate Medicine University of California, San Diego
- PhD Neurosciences University of California, San Diego
Why Is Stewart Alan Factor Influential?
(Suggest an Edit or Addition)Stewart Alan Factor's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
- Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. (2000) (921)
- Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease (2010) (702)
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004) (609)
- Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database (2012) (546)
- Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome (2017) (520)
- Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology (2006) (496)
- Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group (2007) (450)
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. (1999) (417)
- Sleep disorders and sleep effect in Parkinson's disease (1990) (366)
- Psychogenic movement disorders: frequency, clinical profile, and characteristics. (1995) (301)
- Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2 (2012) (274)
- Mutations in GNAL cause primary torsion dystonia (2012) (260)
- A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease (2012) (258)
- A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia (2000) (239)
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
- Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia (1997) (231)
- Cognitive performance of GBA mutation carriers with early-onset PD (2012) (225)
- Occupation and risk of parkinsonism: a multicenter case-control study. (2009) (225)
- Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial (2015) (225)
- Atypical antipsychotics in the treatment of drug‐induced psychosis in Parkinson's disease (2000) (223)
- Longitudinal outcome of Parkinson’s disease patients with psychosis (2003) (219)
- Ropinirole 24-hour prolonged release (2007) (218)
- Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa (2012) (216)
- A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. (2001) (216)
- Parkinson's disease: drug-induced psychiatric states. (1995) (207)
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. (1999) (206)
- Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee (2011) (200)
- Parkinson's Disease: Diagnosis and Clinical Management (2007) (191)
- Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease (1997) (187)
- The focal dystonias: Current views and challenges for future research (2013) (176)
- APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. (2014) (175)
- Clinical presentation and pharmacological therapy in corticobasal degeneration. (1998) (174)
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. (2017) (171)
- SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. (2010) (164)
- The natural history of embouchure dystonia (2001) (159)
- GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease (2016) (157)
- LRRK2 levels in immune cells are increased in Parkinson’s disease (2017) (154)
- Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. (2016) (152)
- Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease (2007) (150)
- Quality improvement in neurology: AAN Parkinson disease quality measures (2010) (149)
- Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk (2008) (145)
- Physiology of freezing of gait (2016) (145)
- Association of Parkinson disease with structural and regulatory variants in the HLA region. (2013) (142)
- The emergin role of clozapine in the treatment of movement disorders (1997) (136)
- Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease (1993) (132)
- Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients (2007) (130)
- Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. (2010) (125)
- Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease (2006) (123)
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) (121)
- LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. (2006) (121)
- NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study (2015) (108)
- The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia (2002) (104)
- Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. (2014) (103)
- Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease (2018) (102)
- Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial (2001) (101)
- Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease (2019) (101)
- Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys (2007) (101)
- Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval (2011) (100)
- Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder (2013) (96)
- Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study (2006) (96)
- The clinical spectrum of freezing of gait in atypical parkinsonism (2008) (95)
- Exploring gene-environment interactions in Parkinson’s disease (2008) (94)
- Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis (2010) (94)
- Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics (2006) (93)
- Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. (1994) (93)
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia (2017) (92)
- A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2017) (92)
- The natural history of the syndrome of primary progressive freezing gait. (2002) (91)
- Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case–control study (2015) (90)
- Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
- Failure of recognition of drug‐induced parkinsonism in the elderly (2008) (89)
- Primary progressive freezing gait: A syndrome with many causes (2006) (88)
- Clozapine prevents recurrence of psychosis in Parkinson's disease (1992) (87)
- A randomized, placebo-controlled trial of latrepirdine in Huntington disease. (2010) (86)
- Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. (2015) (86)
- Head injury, alpha‐synuclein Rep1, and Parkinson's disease (2012) (83)
- Prior history of head trauma in Parkinson's disease (1991) (83)
- A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2 (2010) (82)
- The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease (2015) (81)
- Trauma as an etiology of parkinsonism: A historical review of the concept (1988) (78)
- Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens (2020) (77)
- Freezing of gait: understanding the complexity of an enigmatic phenomenon. (2019) (75)
- People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance (2014) (74)
- The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. (2017) (72)
- Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
- Diagnosis and treatment of dystonia. (2015) (70)
- Quality improvement in neurology: Parkinson disease update quality measurement set (2016) (70)
- Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region (2011) (69)
- Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic (2014) (69)
- Worsening of motor features of Parkinsonism with olanzapine (1999) (68)
- The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. (2000) (66)
- Long-Term Comparative Experience with Tolcapone and Entacapone in Advanced Parkinson's Disease (2001) (65)
- Seizures in juvenile Huntington's disease: Frequency and characterization in a multicenter cohort (2012) (64)
- The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. (1995) (64)
- Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited (2016) (62)
- Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. (2010) (62)
- Identification of a novel Parkinson’s disease locus via stratified genome-wide association study (2014) (61)
- A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease (2008) (60)
- Genetic association between α‐synuclein and idiopathic parkinson's disease (2008) (60)
- Clinical comparison of tardive and idiopathic cervical dystonia (1998) (60)
- Psychogenic tremors (1989) (58)
- Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. (1995) (56)
- Cognitive profile of LRRK2‐related Parkinson's disease (2015) (55)
- Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study (2019) (55)
- A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. (2010) (54)
- Disease‐related and genetic correlates of psychotic symptoms in Parkinson's disease (2011) (54)
- A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease (2012) (54)
- Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease (2001) (54)
- An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy (2000) (53)
- Secondary blepharospasm associated with structural lesions of the brain (2013) (52)
- Freezing of gait subtypes have different cognitive correlates in Parkinson's disease. (2014) (52)
- Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia (2005) (51)
- Current status of symptomatic medical therapy in Parkinson’s disease (2008) (51)
- Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens (2020) (50)
- Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease (2000) (49)
- Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine (2014) (48)
- Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
- β-Hexachlorocyclohexane levels in serum and risk of Parkinson's disease. (2011) (48)
- Peptidoglycan recognition protein genes and risk of Parkinson's disease (2014) (47)
- Cognitive correlates of hallucinations and delusions in Parkinson's disease (2014) (46)
- Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. (2014) (46)
- The role of neurotransmitters in the development of Parkinson's disease‐related psychosis (2017) (45)
- Identification of genetic modifiers of age-at-onset for familial Parkinson’s disease (2016) (45)
- Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: A β-CIT imaging study (2010) (44)
- Focal myopathy as a cause of anterocollis in Parkinsonism (2001) (44)
- Daytime alertness in Parkinson's disease: Potentially dose‐dependent, divergent effects by drug class (2012) (44)
- Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED] (2006) (44)
- Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease (2013) (44)
- Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. (1988) (43)
- Emergency department presentations of patients with Parkinson's disease. (2000) (43)
- Recent developments in drug-induced movement disorders: a mixed picture (2019) (43)
- An open-label study of botulinum toxin A for treatment of tardive dystonia. (1997) (43)
- Cervical dystonia severity scale reliability study (2001) (42)
- Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes (2016) (41)
- Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status (2009) (40)
- Hemichorea‐hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis (1989) (40)
- In vivo detection of lateral–ventral tier nigral degeneration in Parkinson's disease (2017) (38)
- Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. (2013) (37)
- Basal ganglia infarction as a possible cause of cervical dystonia (1993) (37)
- Dopamine agonists (2013) (36)
- Freezing of Gait can persist after an acute levodopa challenge in Parkinson’s disease (2019) (36)
- Adult-onset dystonia. (2011) (36)
- Literature review (2004) (36)
- Movement disorders emergencies Part 2: hyperkinetic disorders. (2011) (36)
- Serum antibodies from Parkinson's disease patients react with neuronal membrane proteins from a mouse dopaminergic cell line and affect its dopamine expression (2006) (35)
- Lack of evidence for an association between UCHL1 S18Y and Parkinson’s disease (2007) (35)
- Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future (2017) (35)
- Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. (2004) (35)
- Excessive daytime sleepiness in cervical dystonia. (2009) (34)
- Focal dystonia secondary to cerebral toxoplasmosis in a patient with acquired immune deficiency syndrome (1991) (34)
- Risperidone and parkinson's disease (2002) (34)
- Early combination therapy with bromocriptine and levodopa in parkinson's disease (1993) (34)
- Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia (2019) (33)
- Sleep and impulsivity in Parkinson's disease. (2013) (33)
- Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: A clinico-pathological case report (1994) (33)
- Fatal Parkinsonism–hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation (2007) (33)
- Possible tardive dystonia resulting from clozapine therapy (1999) (32)
- Daytime REM sleep in Parkinson's disease. (2013) (31)
- How long does it take to diagnose cervical dystonia? (2013) (31)
- Trial of dextromethorphan/quinidine to treat levodopa‐induced dyskinesia in Parkinson's disease (2017) (30)
- Cocaine and tourette's syndrome (1988) (29)
- Delayed‐onset dystonia associated with corticospinal tract dysfunction (1988) (29)
- Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts (2018) (29)
- Vitamin E therapy in Parkinson's disease. (1990) (29)
- Clinimetric testing of the comprehensive cervical dystonia rating scale (2016) (28)
- The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. (2001) (28)
- Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications (2018) (28)
- VMAT2 inhibitors for the treatment of tardive dyskinesia (2018) (28)
- Diabetes mellitus among parkinsonian patients treated chronically with clozapine. (2004) (27)
- A Functional Magnetic Resonance Imaging Study of Head Movements in Cervical Dystonia (2016) (27)
- Temporal profile of improvement of tardive dystonia after globus pallidus deep brain stimulation. (2015) (26)
- Acute delirium after withdrawal of amantadine in Parkinson's disease (1998) (26)
- Tardive dyskinesia due to aripiprazole: report of 2 cases. (2009) (26)
- False‐positive SCA8 gene test in a patient with pathologically proven multiple system atrophy (2005) (25)
- Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease (2017) (25)
- Transient benefit of amantadine in Parkinson's disease: The facts about the myth (1999) (24)
- Dystonia & tremor: A cross-sectional study of the dystonia coalition cohort. (2020) (23)
- Dystonia in AIDS: Report of four cases (2003) (23)
- Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. (2014) (22)
- Paraquat and Parkinson's disease (1987) (21)
- Saccades in Progressive Supranuclear Palsy–Maladapted, Irregular, Curved, and Slow (2017) (21)
- Movement disorders emergencies. Part 1: Hypokinetic disorders. (2011) (21)
- Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. (2006) (20)
- Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson’s disease (2004) (20)
- Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history (2007) (19)
- Propranolol therapy for Tardive dyskinesia: A retrospective examination. (2016) (19)
- Adult‐onset tics associated with peripheral injury (1997) (19)
- Platelet morphology in Parkinson's disease: An electron microscopic study (1994) (19)
- Movement disorders emergencies. (2015) (19)
- Drug-Induced Movement Disorders (1992) (18)
- Psychodynamic Psychotherapy for Functional (Psychogenic) Movement Disorders (2016) (18)
- Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia (2002) (18)
- The initial treatment of Parkinson's disease (2000) (18)
- Pharmacology of atypical antipsychotics. (2002) (17)
- Mosaic pattern of gliosis in the neostriatum of a north american man with craniocervical dystonia and parkinsonism (1997) (17)
- Globus pallidus deep brain stimulation for adult-onset axial dystonia. (2014) (17)
- Tardive Dyskinesia (2011) (15)
- Imaging Parkinsonian Pathology in Substantia Nigra with MRI (2018) (15)
- LRRK 2 levels in immune cells are increased in Parkinson ’ s disease (15)
- Management of Tardive Syndrome: Medications and Surgical Treatments (2020) (14)
- Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson’s Disease. A Perspective (2013) (14)
- Parkinsonism-Hyperpyrexia Syndrome in Parkinson’s Disease (2013) (14)
- Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review (2020) (14)
- Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment (2012) (14)
- Potential mechanisms for low uric acid in Parkinson disease (2016) (13)
- Progressive supranuclear palsy. (2007) (13)
- Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice (2020) (13)
- Propranolol therapy for tardive dyskinesia revisited (2012) (13)
- Clinical subtypes of anterocollis in parkinsonian syndromes (2012) (13)
- The Current Clinical Picture Of Parkinson’S Disease (1988) (13)
- A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson's disease in a bipolar patient (2016) (12)
- Multimodal assessment of nigrosomal degeneration in Parkinson's disease. (2020) (12)
- 'Sleep benefit' in Parkinson's disease (1998) (12)
- Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease (2015) (12)
- Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
- Clinical outcomes of globus pallidus deep brain stimulation for Parkinson disease: a comparison of intraoperative MRI- and MER-guided lead placement. (2020) (12)
- Discussion of Research Priorities for Gait Disorders in Parkinson's Disease (2021) (12)
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–responsive cervical dystonia (1999) (11)
- An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson’s disease (2011) (11)
- Early brain-stem auditory evoked responses in vertebrobasilar transient ischemic attacks. (1987) (11)
- Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease (2020) (11)
- Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease (2018) (11)
- Telemedicine in an Academic Movement Disorders Center during COVID-19 (2021) (11)
- Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease. (1989) (10)
- A Neurodegenerative Disease Sleep Questionnaire: Principal component analysis in Parkinson's disease (2014) (10)
- Ethylene glycol intoxication: a new stage in the clinical syndrome. (1987) (10)
- Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease (1989) (10)
- Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia (2018) (10)
- A Comprehensive Approach to Care in Parkinson's Disease Adds Quality to the Current Gold Standard (2017) (10)
- Clinical outcomes of pallidal deep brain stimulation for dystonia implanted using intraoperative MRI. (2020) (10)
- Chorea caused by lithium intoxication: A case report and literature review (1996) (10)
- Abnormal center of mass feedback responses during balance: A potential biomarker of falls in Parkinson’s disease (2021) (10)
- Lower Limb Rigidity Is Associated with Frequent Falls in Parkinson's Disease (2019) (10)
- Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson’s Disease (2011) (9)
- Exploring human-genome gut-microbiome interaction in Parkinson’s disease (2021) (9)
- Oromandibular Dystonia: A Clinical Examination of 2,020 Cases (2021) (9)
- Parkinson’s disease: Initial treatment with levodopa or dopamine agonists (2001) (9)
- Peripheral catecholamine output in Parkinson's disease: Effects of drug treatment (1995) (9)
- Parkinson’s disease: The treatment of drug-induced hallucinations and psychosis (2001) (9)
- Lurasidone‐Induced Tardive Syndrome (2019) (9)
- Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. (1991) (8)
- Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease (2009) (8)
- Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis (2021) (8)
- Dystonia and Tremor (2021) (8)
- Patient Acceptance and Potential Cost-Savings of Teleneurology in an Academic Outpatient Movement Disorders Practice (P1.022) (2016) (8)
- Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease (2014) (8)
- Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases (2005) (8)
- A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ episodes (2020) (7)
- Occupation and Risk of Parkinsonism (2016) (7)
- Diagnosing functional neurological disorder: seeing the whole picture (2020) (7)
- Perception of whole-body motion during balance perturbations is impaired in Parkinson’s disease and is associated with balance impairment (2019) (7)
- Sleep correlates of trait executive function and memory in Parkinson's disease. (2015) (7)
- The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease. (1989) (7)
- A Metabolomic Study of Cervical Dystonia (2020) (6)
- Diphasic Worsening of Freezing of Gait in Parkinson's Disease (2020) (6)
- Retrospective Evaluation of Vitamin E Therapy in Parkinson's Disease (1989) (6)
- Acetazolamide therapy of menstrual‐related fluctuations in parkinson's disease (1993) (6)
- KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia (PL02.003) (2016) (6)
- Intermittent subcutaneous apomorphine therapy in Parkinson's disease (2004) (6)
- Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial (2020) (6)
- Quality of Life in Parkinson's Disease Patients Following Adjunctive Tolcapone Therapy: Results of an Open-Label, Multicenter, Community-Based Trial (2010) (6)
- Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. (2020) (6)
- It's tricky: Rating alleviating maneuvers in cervical dystonia (2020) (6)
- Parkinson’s disease: Motor fluctuations (1999) (6)
- Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease (2021) (6)
- Neuroleptic Malignant Syndrome (2008) (6)
- Tibial Bone Lead, but Not Serum Polychlorinated Biphenyl, Concentrations Are Associated With Neurocognitive Deficits in Former Capacitor Workers (2013) (5)
- Rapid treatment of “off” episodes (2004) (5)
- Ocular Palatal Tremor Plus Dystonia: New Syndromic Association (2015) (5)
- A Multi‐center Genome‐wide Association Study of Cervical Dystonia (2021) (5)
- The effect of dancing on dystonia (1996) (4)
- Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. (1997) (4)
- Freezing of gait: A rare delayed complication of whole brain radiation. (2016) (4)
- An 18F-FDG PET study of cervical muscle in parkinsonian anterocollis (2014) (4)
- Reliability of the Severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) (S15.001) (2015) (4)
- Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia (TD) (P2.016) (2017) (4)
- Parkinson Disease from long term drug abuse: Meta-analysis of amphetamine/methamphetamine and Parkinson Disease (P6.079) (2018) (4)
- Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension) (S56.005) (2017) (4)
- Head tremor in cervical dystonia: Quantifying severity with computer vision (2022) (4)
- Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities (S56.006) (2017) (4)
- Movement Disorders Emergencies Part 2 (2011) (4)
- 45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study (2019) (3)
- Non‐motor phenotypic subgroups in adult‐onset idiopathic, isolated, focal cervical dystonia (2021) (3)
- Freezing of gait that disappears: Should there be rest before rehab? (2016) (3)
- Dementia in Parkinson’s Disease (2004) (3)
- Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from Three Studies (P2.017) (2017) (3)
- Psychogenic tremors. (1989) (3)
- Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (2022) (3)
- Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review (2022) (3)
- Blockade of Cannabinoid CB 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in MPTP-Treated Rhesus Monkeys (2007) (3)
- A double‐blind evaluation of ciladopa in Parkinson's disease (1987) (3)
- Cerebrospinal fluid Ab42 and fractalkine are associated with Parkinson's disease with freezing of gait (2020) (3)
- Internal consistency of the University of Michigan RBD Questionnaire (2014) (3)
- Cervical dystonia in twins (2002) (2)
- Neuromechanical Assessment of Activated vs. Resting Leg Rigidity Using the Pendulum Test Is Associated With a Fall History in People With Parkinson’s Disease (2020) (2)
- Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) (S56.007) (2017) (2)
- Affective Correlates of Psychosis in Parkinson's Disease (2017) (2)
- Title The RAB 39 B p . G 192 R mutation causes X-linked dominant Parkinson ' s disease Permalink (2015) (2)
- Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial (2022) (2)
- Stepping up to meet the challenge of freezing of gait in Parkinson’s disease (2022) (2)
- The initial treatment of Parkinson's disease. (2000) (2)
- A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2 (S27.007) (2016) (2)
- Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study (P4.075) (2018) (2)
- The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study (2022) (2)
- 134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies (2018) (2)
- Medication-Induced Movement Disorders: VPA, lithium, amiodarone, and other non-DA (2015) (2)
- Treatment of Oromandibular Dystonia (2019) (2)
- The “shirt collar sign” of cervical dystonia (2017) (2)
- Hold that pose: capturing cervical dystonia's head deviation severity from video (2022) (2)
- Secondary Causes of Parkinsonism (2000) (2)
- Initiating therapy in Parkinson's disease (2009) (2)
- Faculty Opinions recommendation of Pain in Parkinson's disease: Prevalence and characteristics. (2010) (2)
- Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
- From Null to Midline: Changes in Head Posture do Not Predictably Change Head Tremor in Cervical Dystonia (2022) (1)
- Current and Emerging Treatments for Cervical Dystonia (2000) (1)
- Treatment of Multiple System Atrophy (2019) (1)
- 46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study (2019) (1)
- Letters to the editor (2000) (1)
- Nonmotor Symptoms in Dystonia (2006) (1)
- 134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study (2020) (1)
- Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) (S56.004) (2017) (1)
- Advanced therapies for movement disorders in neurotherapeutics (2008) (1)
- Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study (P4.078) (2018) (1)
- Treatment of tardive dystonia: A review (2023) (1)
- Pseudonystagmus in progressive supranuclear palsy (2022) (1)
- Phosphodiesterase 4 (2017) (1)
- Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson’s disease (2020) (1)
- The role of polymyography in the treatment of cervical dystonia: the authors reply (2016) (1)
- PD-1102: A Phase 1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson’s Disease and Motor Fluctuations (P1.8-017) (2019) (1)
- Human-genome gut-microbiome interaction in Parkinson’s disease (2021) (1)
- Clozapine (1994) (1)
- James Parkinson: The Man and the Essay (2002) (1)
- Current and future treatments in multiple system atrophy (2007) (1)
- Comparing Quality of Parkinson Disease Care in a Comprehensive Clinic to Specialist Care (P6.372) (2016) (0)
- P2.067 Resolving mode-of-inheritance and association of PRKN with PD in a comprehensive sequence and copy-number-variation (CNV) analysis of 3800 subjects (2009) (0)
- Metoclopramide therapy for migraine: worth the risk? (2018) (0)
- Physiological measures and anatomical correlates of subthalamic deep brain stimulation effect on gait in Parkinson's disease (2023) (0)
- Faculty Opinions recommendation of Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. (2011) (0)
- P2.048 Screening and selection process for deep brain stimulation: the Emory experience (2009) (0)
- Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia (2018) (0)
- P3.039 Polymorphisms in the transcription factor gene GATA2 and GATA-2 target region in a-synuclein (SNCA) are associated with Parkinson's disease (PD) (2009) (0)
- Third Annual Huntington Disease Clinical Research Symposium (2011) (0)
- Editorial: Neurotherapeutics of Movement Disorders (2013) (0)
- Combination therapy for PD (1993) (0)
- Delineation of the Clinical Features and Treatment Response of Oromandibular Dystonia: A Multicenter Summary of 2,057 Cases. (2020) (0)
- Explorer Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson ' s disease (2017) (0)
- An Explainable Spatial-Temporal Graphical Convolutional Network to Score Freezing of Gait in Parkinsonian Patients (2023) (0)
- Initiating Therapy in Parkinson's Disease. Authors' reply (2009) (0)
- Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease (2023) (0)
- Clinimetric Testing of the Modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS) (S27.004) (2014) (0)
- DIAGNOSTIC CONSIDERATIONS IN EVALUATING GERIATRIC PATIENTS WITH MOVEMENT DISORDERS (2019) (0)
- Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson’s Disease. A Perspective (2013) (0)
- Levodopa Responsiveness Subtypes of Freezing of Gait: Results Using a Levodopa Challenge (2019) (0)
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study (2022) (0)
- Clinical characteristics of oromandibular dystonia: A multicenter review of 201 caseS (2016) (0)
- LRRK2 levels in immune cells are increased in Parkinson’s disease (2017) (0)
- Restless Legs Symptoms and Periodic Leg Movements in Sleep Among Patients with Parkinson's Disease. (2022) (0)
- Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis (2021) (0)
- Cramps and Spasms (2008) (0)
- Reversibility of Tardive Syndromes (P04.031) (2012) (0)
- 151 Confirmed Safety of Deutet.rabenazine for Tardive Dyskinesia in a 3-Year Open-Label Extension Study (2020) (0)
- Comprar Parkinson's Disease | Stewart A. Factor | 9781933864006 | Demos Medical Publishing (2007) (0)
- 139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study (2020) (0)
- Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
- The Effects of Thalamic Deep Brain Stimulation on Gait in Essential Tremor: a Kinematic Study. (P7-11.001) (2023) (0)
- Kevin Delgado Barron, MD (1929–2013) (2014) (0)
- 158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study (2018) (0)
- Reply to: “Letter on Discussion of Gait Research” (2022) (0)
- Third Annual Huntington Disease Clinical Research Symposium : Organized by the Huntington Study Group (Huntington Study Group Abstracts) (2010) (0)
- A Comprehensive Approach to Parkinson’s Disease (P4.052) (2014) (0)
- Head tremor after a remission of spasmodic torticollis. (1990) (0)
- Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia. (2021) (0)
- William J. Weiner, MD (1945–2012) (2013) (0)
- Reduced norepinephrine transporter binding in Parkinson's disease with dopa responsive freezing gait (2022) (0)
- Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration (1996) (0)
- Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
- Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. (2023) (0)
- Treatment of Serotonin Syndrome (2019) (0)
- Faculty Opinions recommendation of Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. (2011) (0)
- In Memoriam: William J. Weiner, MD: June 28, 1945–December 29, 2012 (2013) (0)
- Faculty Opinions recommendation of The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. (2010) (0)
- Biomechanical outcomes of the pendulum test characterize individual differences in activated versus resting leg rigidity in people with Parkinson's disease (2020) (0)
- P2.110 Evidence for association of high-dose levodopa therapy with intellectual and psychiatric complications of Parkinson's disease (2009) (0)
- Camptocormia: a consensus for grading on a curve. (2018) (0)
- Exploring human-genome gut-microbiome interaction in Parkinson’s disease (2021) (0)
- Patients with Cognitive Impairment in Parkinson's Disease Benefit from Deep Brain Stimulation: A Case‐Control Study (2023) (0)
- 149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study (2018) (0)
- Clinical Outcomes Of Deep Brain Stimulation Placement Using Intraoperative MRI for Parkinson Disease (P3.359) (2016) (0)
- Appendix D: Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidenced-based review): Report of the Quality Standards Subcommitte of the American Academy of Neurology (2007) (0)
- Quantitative tremor analysis of Holmes tremor: a case series (P6.066) (2018) (0)
- Deep Brain Stimulation Placement Using Intraoperative MRI for Dystonia: One Year Clinical Outcomes (S30.003) (2016) (0)
- Identification of a novel Parkinson’s disease locus via stratified genome-wide association study (2014) (0)
- Clinical Characteristics and Natural History of Oromandibular and Lingual Dystonia (P5.399) (2016) (0)
- Impact of Deep Brain Stimulation on Gait in Parkinson Disease: A Kinematic Study (2022) (0)
- Treatment of Tardive Dyskinesia (2019) (0)
- Driving and the Elderly (2002) (0)
- An explainable spatial-temporal graphical convolutional network to score freezing of gait in parkinsonian patients (2023) (0)
- Deep Brain Stimulation for Tremor in Parkinson’s Disease (2019) (0)
- Phenotyping Motor-subtypes of Parkinsonism from Full-body Kinematics using Machine Learning (P6-11.007) (2023) (0)
- COMBINATION THERAPY FOR PD. AUTHOR'S REPLY (1993) (0)
- Clinical and Genetic Characteristics of Participants with Juvenile PD: The CORE-PD Study (IN10-2.001) (2012) (0)
- Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder (2013) (0)
- Impact of age or time to treatment on changes in clinical outcome scores in patients treated with tPA (tissue plasminogen activator) for acute ischemic stroke: The Loyola University Medical Center (LUMC) experience (2010) (0)
- Review for "Is freezing of gait correlated with postural control in patients with moderate‐to‐severe Parkinson’s disease?" (2020) (0)
- Long-Term Efficacy and Safety of Deutetrabenazine in Patients with Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use (2022) (0)
- Medical Therapy for Fluctuations in Parkinson’s Disease (2019) (0)
- Long-Term Deutetrabenazine Treatment Is Associated With Continued Improvement in Tardive Dyskinesia in the Completed 3-Year Open-Label Extension Study. (2021) (0)
- Reply (2000) (0)
- Letter to the editor (0)
- Ropinirole as compared with levodopa in Parkinson's disease. (2000) (0)
- The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease (2015) (0)
- Estimating the Cumulative Risk of PD in Carriers of Parkin Mutations: The CORE-PD Study (PD4.007) (2012) (0)
- Efficacy and safety of Valbenazine (NBI-98854) in subjects with tardive dyskinesia: Results of a long-term study (KINECT 3 extension) (2018) (0)
- Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders (2022) (0)
- Freezing of Gait can persist after an acute levodopa challenge in Parkinson’s disease (2019) (0)
- Letters to the editor (0)
- Lower-limb rigidity is associated with frequent falls in Parkinson disease (2019) (0)
- Faculty Opinions recommendation of Smoking duration, intensity, and risk of Parkinson disease. (2010) (0)
- Treatment of Drenching Sweats in Parkinson’s Disease (2019) (0)
- Data-Driven Discovery of Novel Motor Biomarkers for Freezing-of-Gait in Parkinsonism from Full-body Kinematics using Artificial Intelligence (P6-11.001) (2023) (0)
- Editorial: Neurotherapeutics of Movement Disorders (2013) (0)
- Poster 3: Frequency of Epileptic Seizures in a Population of Juvenile Huntington's Disease Patients (2010) (0)
- Neurodegenerative Disease Sleep Questionnaire (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stewart Alan Factor?
Stewart Alan Factor is affiliated with the following schools: